Pharmaceutical

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.

Sep 18, 2024 - 04:00
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.
Read the original article

Tags:

Previous Article

Podcast: How drones are transforming the clinical supply chain in Africa

Next Article

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Actimed plans trials to treat muscle wasting syndrome in cancer patients

Actimed plans trials to treat muscle wasting syndrome i...

Jul 13, 2023

Pharmaceutical drug delivery market and systems

Pharmaceutical drug delivery market and systems

Mar 24, 2024

STAT+: Patients loved Carbon Health’s diabetes program. That couldn’t save it

STAT+: Patients loved Carbon Health’s diabetes program....

Nov 13, 2023